GlassScriptPhysician profile
Frank C Koranda
NPI 1871560045
$9,184.37
in general payments reported to CMS, 2019-2025
32 companies · $626 in 2025
The $626 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,435 · 2020: $220 · 2021: $232 · 2022: $306 · 2023: $525 · 2024: $842 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.47 |
| Education | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,925.92 | 2019-2021 | |
| Abbvie INC. | $861.20 | 2019-2025 | |
| Organogenesis INC. | $492.32 | 2019-2025 | Affinity, Puraply, Puraply Wound Matrix |
| E.R. Squibb & Sons, L.L.C. | $248.45 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $192.48 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $156.35 | 2021-2023 | Ilumya |
| Glaxosmithkline, LLC. | $106.86 | 2023-2025 | Nucala |
| Dermavant Sciences, INC. | $103.77 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $101.17 | 2024 | Tremfya |
| Ucb, INC. | $88.43 | 2024 | Bimzelx |
| Leo Pharma INC. | $88.35 | 2022-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $81.89 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $80.90 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.78 | 2019-2025 | Libtayo |
| Amgen INC. | $65.44 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $58.76 | 2024 | |
| Celgene Corporation | $55.18 | 2019 | |
| Genentech, INC. | $49.95 | 2024 | Erivedge |
| Fresenius Kabi USA, LLC | $48.65 | 2023 | Idacio |
| Optinose US, INC. | $45.96 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $43.10 | 2025 | Acthar |
| Hologic Sales and Service, LLC | $33.19 | 2023 | Coolseal Generator |
| Stryker Corporation | $25.52 | 2022 | |
| Grifols USA, LLC | $24.87 | 2023 | Xembify |
| Kowa Pharmaceuticals America, INC. | $23.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.90 | 2024 | Tremfya |
| Biofrontera INC. | $17.99 | 2022 | |
| Kerecis Limited | $17.84 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Galderma Laboratories, L.P. | $17.34 | 2024 | |
| Almirall LLC | $13.90 | 2021 | |
| Pfizer INC. | $13.24 | 2022 | |
| Dermira, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Koranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.